Loading...
HomeMy WebLinkAboutResolution - 2007-R0523 - Amendment To Agreement - Maxorplus LTD- Pharmacy Benefits Management - 11_08_2007Resolution No. 2007-RO523 November 8, 2007 Item No. 5.2 RESOLUTION BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF LUBBOCK: THAT the Mayor of the City of Lubbock BE and is hereby authorized and directed to execute for and on behalf of the City of Lubbock, an Amendment to a Pharmacy Service Agreement dated April 1, 2006, for pharmacy benefits management and provision of prescription drugs for all participants of the City of Lubbock Health Benefits Plan between MaxorPlus, Ltd. and the City of Lubbock, and related documents. Said Amendment is attached hereto and incorporated in this resolution as if fully set forth herein and shall be included in the minutes of the City Council. Passed by the City Council this 8th day of November , 2007. DAVID A. MILLER, MAYOR TTEST: S� Rebecca barza, e-��, <-9-� City Secretary OVED AS TO CONTENT: Hutchenson, Director of Risk Management 'APPROVED AS TO FORM: IYAmendment. MaxorP 1us.res0 8 Oct. 31, 2007 Resolution No. 2007-RO523 AMENDMENT TO CONTRACT This Amendment to Contract ("Amendment") is entered into by and between the City of Lubbock, Texas, a Texas home -rule municipality (the "City") and MaxorPlus, Ltd. ("Maxor"). RECITALS WHEREAS, the City and Maxor entered into a certain Pharmacy Service Agreement (the "Agreement") dated April 1, 2006 whereby Maxor would provide pharmacy benefit management services to the City; and WHEREAS, the Agreement provides that the Agreement may not be modified except by written, signed agreement of the parties; and WHEREAS, the Agreement had attached thereto a Summary of Prescription Benefit Coverage marked as "Exhibit C — Prescription Drug Rider"; and WHEREAS, the parties to the Agreement now desire to amend the Agreement by placing a revised Summary of Prescription Benefit Coverage into the Agreement in substitution of the current summary, to be effective so as to reflect more accurately the benefits the City wishes to offer to its employees, effective January 1, 2008; and WHEREAS, the parties desire that all other terms and conditions of the Agreement shall remain in full force and effect. THEREFORE, in consideration of the mutual covenants and promises of the parties, as well as for ten dollars and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the undersigned, the parties hereto agree to amend the Agreement as follows: 1. Effective January 1, 2008, Exhibit "C" to the Agreement is hereby stricken in its entirety and replaced with Exhibit "C2,° attached hereto and incorporated herein for all purposes, with said Exhibit "C2" being made a part of the Agreement, as though fully set forth therein. 2. Effective January 1, 2008, all references to "Exhibit C" in the Agreement shall be read as references to "Exhibit C2." To the extent of any other conflict between the Agreement and this Amendment, the Amendment shall control; provided, however, that the mere absence of a provision in the Amendment shall not be deemed on that basis alone to be a conflict with an existing provision in the Agreement. The undersigned additionally represent their authority to execute this Amendment, and to bind their respective entities hereto. The following exhibit is attached hereto and made a part of this Amendment: 1. Exhibit "C2" — City of Lubbock Summary of Prescription Benefit Coverage Amendment to Contract — MaxorPlus, Ltd. Page 1 of 2 EXECUTED on 8th day of November, 2007. MAXORPLUS, LTD. Joh*6 Q. Ward, Chief Executive Officer CITY OF LUBBOCK SO&.i/ DAVID ATTEST: -r Rebe ca Garza, City Secretary APPROVED AS TO CONTENT: Leisa Hutcheson, Risk Management c- .rf� fi ',- - - Amendment to Contract - MaxorPlus, Ltd. Page 2 of 2 Exhibit C2 City of Lubbock Summary of Prescription Benefit Coverage Effective January 1, 2008 Covered Items • Accutane and generics- through age 25 • Amphetamines / ADD drugs • Compounded medications of which at least one ingredient is a legend drug • Contraceptives — oral, injectables, intravaginal (Nuvaring) and transdermal only • Contraceptives, emergency (ex. Preven, Plan B)- retail pharmacies only • DESI drugs • Diabetic supplies — (lancets/lancet devices, insulin pens/syringes/needles, test strips) • Differin • Folic acid • Glucometers and calibration/control solutions • Growth hormones- restricted to Maxor Specialty • Hemophelia factors- restricted to Maxor Specialty • Homeopathic/natural legend products • Injectables on List COL COV INJ • Insulin • Iron supplements (Rx only) • Legend drugs, except for drugs listed as exclusions • Respiratory Therapy Supplies- aerochambers, spacers, peak flow meters • Relenza- covered only at retail • Smoking deterrents (Rx only — example Patches, tablets, nasal spray) • State Restricted Drugs • Syringes/needles, other than insulin type • Tamiflu- covered only at retail • Topical tretinoins (ex. Avita, Retin-A)-through age 25 • Vitamins- pediatric, prenatal (Rx only) • Wound dressings Drugs Requiring Prior Authorization - None Drugs with Special Quantity Limits- • Depo-Provera- 90 day supply allowed for one retail copay • Estring- 90 day supply allowed for one retail copay • Seasonale- 91 day supply allowed for one retail copay • Smoking Deterrents- Limited to 2 treatment courses (12 wks each) per lifetime Excluded Items • Accutane and generics- ages 26 & up • Agents for weight loss • Anti-sera/immune globulins • Allergy serums/extracts • Anti -wrinkle agents (ex. Renova) • Blood or blood plasma • Contraceptives devices (ex. Diaphragms, IUDs) • Contraceptives, emergency (ex. Preven, Plan B)- excluded from mail • Contraceptive implants • Cosmetic hair removal products (ex. Vaniqa) • Depigmenting agents (ex. Hydroxyquinone) • Dental products • Devices, appliances, or supplies, including support garments & non -medicinal substances • Drugs indicated for cosmetic uses 10-07-APREV Exhibit C2 City of Lubbock Summary of Prescription Benefit Coverage Effective January 1, 2008 Excluded Items (continued) • Drugs for sexual dysfunction • Fertility agents • Fluoride supplements • Hair growth stimulants • Immunization agents/vaccines • injectables, other than those listed as included • Mifeprex • Minoxidil, topical • Non -legend drugs (OTC's) • Nutritional supplements • Relenza- excluded at mail • Tamiflu- excluded at mail • Topical tretinoins (ex. Avita, Retin-A)- ages 26 & up • Toxoids • Vitamins (All excluding prenatal and pediatric, vitamin K and vitamin B-12) Days Supply Retail- 30 days Mail- 90 days Edit for 75% usage before refills allowed Copays Retail- Tier-1 (Generic): $5.00 Tier-2 (Preferred Brand): $30.00 Tier-3 (Non -Preferred Brand): $50.00 Mail- Tier-1 (Generic): $12.50 Tier-2 (Preferred Brand): $75.00 Tier-3 (Non -Preferred Brand): $125.00 *Note: if member or physician requests a brand name drug with a generic available, the member is responsible for the brand/generic differential plus applicable brand copay. 10.07-APREV Exhibit C2 City of Lubbock Summary of Prescription Benefit Coverage Effective January 1, 2008 Inlectables Covered At Retail/Mail Order Network Pharmacies Anaphylactic Kits (ex. Epi-pen, Anakit) Byetta Calcitonin (Miacalcin) Cyanocobalamin (Vitamin B-12) Desmopressin (DDAVP) Dihydroergotamine (D.H.E.-45) Glucagon Imitrex Insulin Symlin Vitamin K Xolair- limited distribution lniectables Covered Through Maxor Specialty Pharmacy Actimmune Alferon-N Apokyn Aranesp Arixtra Avonex Betaseron Copaxone Eligard Enbrel Epogen Forleo Fuzeon Fragmin Geref Growth Hormones/Growth Hormone Releasing Hormones Histrelin Humatrope Humira Infergen Innohep Interferons ntron-A Kineret Leukine Leuprolide Lovenox Lupron/Lupron Depot Myeloid Stimulants Neumega Neupogen Norditropin Normiflo Nutropin/Nutropin AQ Octreotide Orgaran Procrit Protropin Raptiva Rebelron Rebif Roferon-A Saizen Sandostatin Serostim Somavert Supprelin 10-07-APREV Exhibit C2 City of Lubbock Summary of Prescription Benefit Coverage Effective January 1, 2008 Non-Iniectables Covered Through Maxor Specialty Pharmacy Only Arava Copegus iressa Nebupent Pulmozyme Rebetol Ribasphere Ribavirin Sensipar Stimate Nasal Spray Tarceva Temodar Tobi Valcyte Virazole Xeloda Client Signature City of Lubbock Date 10-07-APREV Resolution No. 2006-ROI March 8, 2006 Item No. 5.10 RESOLUTION BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF LUBBOCK: THAT the Mayor of the City of Lubbock BE and is hereby authorized and directed to execute for and on behalf of the City of Lubbock, a Contract for pharmacy benefits management and provision of prescription drugs for all participants of the City of Lubbock Health Benefits Plan between MaxorPlus, Ltd. and the City of Lubbock, and related documents. Said Contract is attached hereto and incorporated in this resolution as if fully set forth herein and shall be included in the minutes of the City Council. Passed by the City Council this 8th day of March , 2006. MAkC;KICDOUGAL, MAYOR ATTEST: 2� Rebecca Garza, City Secretary APPROVED AS TO VAA Scott Snider, Director of Human Resources APPROVED AS TO FORM: IN i l' i vorney gs/res. MaxorP lus March 1, 2006 MAXORPLUS, LTD. PHARMACY SERVICE AGREEMENT This Pharmacy Service Agreement (the "Agreement"), dated as of April 1, 2006 (the "Effective Date"), is between MaxorPlus, Ltd., ("MAXORPLUS") and City of Lubbock ("CLIENT"). WHEREAS, MAXORPLUS is engaged in the business of providing to various customers pharmacy benefit management services, including prescription drug benefit design, participating pharmacy contracting and network management, eligibility management, claims processing, reporting, and clinical pharmacy services. WHEREAS, CLIENT offers prescription drug benefits to eligible employees, dependents and retirees; and WHEREAS, CLIENT intends to engage MAXORPLUS to perform the pharmacy benefit management services required by CLIENT to fulfill its obligations to the eligible persons with whom it has contracted; and WHEREAS, CLIENT desires disclosure of all charges and discounts associated with its prescription drug benefit program; and WHEREAS, CLIENT requires the lowest available purchase price and pass through pricing from its pharmacy benefit manager on all of its drugs purchased through a retail pharmacy network or through a mail order pharmacy; and WHEREAS, MAXORPLUS is qualified to perform such services and is willing to do so through a COMPLETE DISCLOSURE PROGRAM upon and subject to the terms and conditions of this Agreement; WHEREAS, MAXORPLUS pledges to provide the Pharmacy Benefit Management Services under this contract in accordance with the Code of Ethics set forth in Exhibit E; NOW, THEREFORE, in consideration of the mutual promises and agreements herein contained, CLIENT and MAXORPLUS hereby agree as follows: A. Definitions AWP — "AWP" means the price defined and distributed by First Data Bank for each drug in the database. This price shall be based on the 11 digit NDC number submitted forthe dispensed medication. AWP prices will be updated in the claims processing system at least on a weekly basis to reflect the most current AWP pricing. Co -Payment — "Co -Payment" means the amount of money that, according to the terms of the Plan, the Eligible Member is required to pay towards the receipt of a Covered Prescription Medication provided by a Participating Pharmacy. MaxorPlus Initials CLIENT Initials: Covered Prescriptions — "Covered Prescriptions" means any prescription medication or device that meets the requirements for coverage set forth in the Prescription Drug Rider, after applying all conditions and exclusions set forth therein, and that is dispensed by a Participating Pharmacy to an Eligible Member. Eligible Member — "Eligible Member" means an individual who is enrolled in the Plan and who is entitled to Covered Prescription Medications under the Prescription Drug Rider for the Plan. Information relating to the eligibility of members is established and maintained by CLIENT. Formulary— "Formulary" means the document prepared by MAXORPLUS or CLIENT and provided to Participating Pharmacies, physicians, and other health care providers for the purpose of guiding the prescribing, dispensing and purchase of pharmaceutical products. Law — "Law" means any federal, state or local constitution, act, statute, code, rule, regulation, standard; any objective criteria contained in any applicable permit or approval; any legislative or administrative action of the United States of America or of any state or agency, department, authority, political subdivision or other instrumentality thereof; and any decree, judgment or order of a court. Manufacturers — "Manufacturers" shall mean a pharmaceutical company which has entered into an agreement with MAXORPLUS or an affiliate or agent of MAXORPLUS to offer rebates for pharmaceutical products in connection with Formulary services. Maximum Allowable Cost (MAC) — "MAC" means the lowest published price for a Covered Prescription, as set forth on the applicable CMS MAC list, Texas state list or the MaxorPlus MAC list. The MAC will be determined without regard to the manufacturer of the Covered Prescription actually dispensed by a Participating Pharmacy. Net Acquisition Cost — "Net Acquisition Cost" means MaxorPlus' unit price for pharmaceutical products as invoiced by the wholesaler or manufacturer to MaxorPlus Mail Order Pharmacy. Participating Pharmacy [or Participating Pharmacies] — "Participating Pharmacy" or "Participating Pharmacies" means those pharmacies with whom MAXORPLUS has contracted to provide various services in connection with the sale by those pharmacies of Covered Prescriptions to Eligible Members, as listed in the MAXORPLUS Pharmacy Directory. Patient Profile — "Patient Profile" means a specific history of drugs dispensed by a Participating Pharmacy to an Eligible Member. The history shall include information on drugs dispensed, allergies, and the Eligible Member's general health condition, if available. Pharmacy Benefit Management Services — "Pharmacy Benefit Management Services" means those services described in paragraph B of this Agreement that MAXORPLUS provides to CLIENT. MaxorPlus Initials: CLIENT Initials: Physicians — "Physicians" means licensed physicians and other providers who have contracted to provide services to Eligible Members and who are authorized by the Plan to write prescriptions for Eligible Members. Plan — "Plan" means the agreement or other arrangement between an Eligible Member and CLIENT that entitles the Eligible Member to receive reimbursement for, or payment of, medical expenses, including, without limitation, Covered Prescriptions. Point -of -Safe (POS) — "POS" means the method of submitting claims for adjudication by the on-line claim adjudication process of MAXORPLUS which includes interactive communications between a terminal located at a Participating Pharmacy and MAXORPLUS. POS Approval — "POS Approval" means approval by MAXORPLUS via Point -of -Sale (POS) claim submission of a claim for reimbursement of, or payment for, a Covered Prescription by a Participating Pharmacy. Prescription — "Prescription" means a lawful written, electronic or verbal order of a health care practitioner licensed for a particular medication. Prescription Drug Rider — "Prescription Drug Rider" means the prescription drug benefit coverage, limitations and exclusions set forth in the Plan, as amended from time to time by the CLIENT. Proprietary or Confidential Information -- "Proprietary or Confidential Information" means any information, however recorded, related to performance, sales, financial, contractual, and marketing information; software; technical data; the Formulary; and concepts and processes, which have not (i) previously been published or otherwise disclosed to the general public; (ii) previously been made available to the receiving party or others without restrictions, or (iii) normally been furnished to others without compensation, and which the disclosing party desires to protect against unrestricted disclosure or competitive use. Rebates — "Rebates" shall mean for any period, rebates, reimbursements or other discounts received under a manufacturer's rebate program with respect to pharmaceutical products dispensed to an Eligible Member under the Plan during such period. Usual and Customary Pricing — "Usual and Customary Pricing" means the lowest price a Participating Pharmacy would charge to a patron, who is not an Eligible Member, if that patron were to pay cash for a Covered Prescription. Such price shall reflect any incentive or other discounts offered to the patron by Pharmacy. B. MAXORPLUS Services. MAXORPLUS shall provide the following products and services to CLIENT in accordance with the Plan: MaxorPlus Initials: AZ CLIENT Initials: 1. Pharmacy Benefit Management Services (a) Network of Participating Pharmacies. MAXORPLUS will enter into contracts with Participating Pharmacies pursuant to which those Participating Pharmacies will agree to dispense Covered Prescriptions to Eligible Members and MAXORPLUS will agree to pay or reimburse the Participating Pharmacies for Covered Prescriptions dispensed by them to Eligible Members. MaxorPlus agrees to invoice CLIENT on the same discounted AWP price or MAC price that MaxorPlus pays the network pharmacy. (b) Claims Processing and Adjudication. MAXORPLUS will accept, process and adjudicate requests for authorization to dispense Covered Prescriptions submitted by Participating Pharmacies through the MAXORPLUS POS system. (c) Customer Service. MAXORPLUS will maintain and operate toll -free customer service lines for the benefit of Participating Pharmacies and Eligible Members from 7:00 a.m. to 9:00 p.m. Central Standard or Daylight Time, Monday through Friday, and 8:00 a.m. to 6:00 p.m. Central Standard or Daylight Time, Saturday and 9:00 a.m. to 5:00 p.m. Central Standard or Daylight time, Sunday (excluding holidays). (d) Formulary Management. MAXORPLUS will assist Client in developing a Formulary for the Plan. CLIENT hereby authorizes MAXORPLUS to manage the Formulary for prescription drug benefits covered under the Plan for retail and mail order Covered Prescriptions dispensed in accordance with this Agreement. The cost of postage, printing, and distribution of the Formulary and any subsequent update thereto or reports hereunder will be borne by the CLIENT as set forth in Exhibit "A" under Administrative Services and Fees. CLIENT agrees that MAXORPLUS may certify to MAXORPLUS' contracting pharmaceutical manufacturers that CLIENT is participating in such Formulary Program for the CLIENTS' retail and mail order Covered Prescriptions as provided herein. CLIENT acknowledges that MAXORPLUS maintains a Formulary that allows, subject to the determination of an independent pharmacy and therapeutics committee, the inclusion of any covered prescription drug product approved by the FDA for use in the United States. CLIENT'S formulary will be identified in Exhibit C and made available to CLIENT. (e) Rebate Contracts. MAXORPLUS will attempt to contract with certain manufacturers for rebate programs. CLIENT acknowledges that whether and to what extent manufacturers are willing to provide rebates to CLIENT will depend upon the Plan design adopted by CLIENT, and the Formulary used. The CLIENT recognizes that MAXORPLUS' Clinical, PharmacoEconomic, and Rebate Departments have negotiated contracts with manufacturers which will result in rebates being paid by manufacturers. MAXORPLUS will pass through to CLIENT all rebates received on the pharmaceutical products dispensed to members once each calendar quarter as follows: within ninety (90) days of the beginning of each quarter, MAXORPLUS will pay CLIENT such rebates received. MAXORPLUS shall not be required to institute litigation to collect rebates from manufacturers. If MAXORPLUS does elect to bring suit to recover rebates from MaxorPlus Initials: CLIENT Initials: manufacturers, MAXORPLUS shall be entitled to deduct all reasonable attorney's fees and other expenses incurred in such litigation prior to payment of the rebates to CLIENT. Neither party shall be responsible to the other party, its affiliates, directors, employees, agents, successors, and permitted assigns for any claim arising from: (i) any failure by a manufacturer to pay any rebate; (ii) any breach of an agreement relating to the transactions contemplated by or otherwise relating to this Agreement by any manufacturer; or (iii) any negligence or misconduct of any manufacturer. To the extent that an ERISA, the ADA, or any other law, requires any disclosure to Eligible Members regarding Rebates or other discounts on pharmaceutical products, CLIENT acknowledges that it has the sole responsibility for such disclosures to its Eligible Members. (f) Drug Utilization Reviews and Interaction Monitoring. MAXORPLUS will provide to Participating Pharmacies through the POS system computerized drug interaction monitoring of Eligible Members based upon the available Patient Profile and, subject to prescriber approval and applicable Law, will provide Drug Utilization and pharmaceutical cost containment ("DUR") services, including generic and therapeutic substitutions. (g) Limitations on Drug Utilization Review Services. The information generated in connection with DUR services is intended as an economical supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of physicians, pharmacists, or other healthcare providers and patient care. Providers are individually responsible for acting or not acting upon information generated and transmitted through the DUR services, and for performing services in each jurisdiction consistent with the scope of their licenses. In performing DUR services, MAXORPLUS shall not, and is not required by this Agreement to deny claims or require physicians, pharmacists, or patient compliance with any norm or suggested drug regimen, or in any way substitute MAXORPLUS' judgment for the professional judgment or responsibility of the physician or pharmacist. MAXORPLUS' DUR services are highly automated. Any focus professional review would also be based upon automated analysis of eligible members' profiles. Therefore, the DUR services are necessarily limited by the amount and type of patient information available to MAXORPLUS. Meaningful patient information which may not be available to MAXORPLUS includes, but is not limited to, patient diagnosis, utilization of drugs obtained without utilizing the MAXORPLUS POS System or otherwise not included in the patient's profile or claim data. MAXORPLUS shall have no obligation to acquire information concerning any patient beyond the information which is included in the CLIENT'S eligibility records or the claim data submitted by the participating pharmacies in connection with the Plan. MAXORPLUS shall update its DUR databases on a reasonable basis to reflect changes in available standards for pharmaceutical prescribing; provided, however, no data base will be required to contain all currently available information on accepted medical practices or prescribing practices. 5 MaxorPlus lnitials: CLIENT Initials: (h) Maintenance of Records/Audit/Member Review. MAXORPLUS will maintain such business records as may be required by Law or as may be necessary to properly document the delivery of, and payment for, Covered Prescriptions ("Claims Information") and the provision of services by MAXORPLUS under this Agreement. Such records may be reviewed by CLIENT or its representatives upon 48 hours prior request and at CLIENT'S expense; provided, however, that no such review shall relate to records for Covered Prescriptions dispensed more than two (2) years prior to the date such review is requested. Should MaxorPlus' supply contract prohibit disclosure of such contract, MaxorPlus will provide satisfactory documentation to verify pricing, discounts and rebates. If an Eligible Member or a Member's agent or designee shall request to review or duplicate any records of that Member's claims' information, MAXORPLUS shall refer such member to CLIENT, which may request any such records under this paragraph. Compliance with random or specific data sampling requests shall require thirty (30) days prior written notice. In the case of review by representatives of CLIENT, such representatives shall agree in writing to abide by the confidentiality and indemnity provisions of this Agreement. Except as required by Law, MAXORPLUS shall not make any of its records available to others for any purpose otherthan the provision of products and services under this Agreement; provided, however such data may be combined and used by MAXORPLUS in preparing statistical reports or for other business purposes that may be made available to others, in which event information pertaining to CLIENT or Eligible Members shall not be identifiable. If MAXORPLUS receives a court order, subpoena, or governmental request for such records; MAXORPLUS may comply with such order, subpoena, or request and, if such order, subpoena, or request relates to the records of the CLIENT or any Eligible Member and not to MAXORPLUS' businesses generally, CLIENT shall reimburse MAXORPLUS for all costs incurred in connection therewith. (i) MaxorPlus will not use repackaged or relabeled NDC numbers for mail order pricing unless the unit AWP is less than the un-repackaged price which MaxorPlus would have paid. 2. Mail Order Service Pharmac MAXOR MAIL SERVICE PHARMACY will provide to client members the following services: (a) Fill Prescriptions by mail during normal business hours, subject to the professional judgment of the dispensing Pharmacist; and (b) Based upon the Prescriptions actually written and applicable Law, maintain an inventory equal to a ninety (90) day supply for each Prescription. CLIENT acknowledges that Maxor Mail Service Pharmacy has negotiated on behalf of MAXORPLUS contracts with prime vendors which result in substantial discounts but which contracts require Maxor Mail Service to prepay such vendors, and that MAXORPLUS passes on such prepayment discounts to CLIENT. 3. Chronic Iniectable/Specialty Pharmacy. MaxorPlus Initials: CLIENT Initials: Maxor Specialty will be the exclusive provider of chronic injectables, biological medications and specialty oral medications and will provide to client members the following services: (a) Fill prescriptions by mail, common carrier or overnight as dictated by stability requirements of medications, during normal business hours (b) Coordination of nursing services as required (c) 24 hour pharmacy education and consultation (d) Home or office delivery (e) Patient monitoring and follow-up for compliance and outcomes (f) Other infusion services (g) Coordination of benefits (h) Contact insurance company to verify coverage under medical benefit (i) Toll -free customer service phone number 4. Additional Services. If (i) CLIENT requests MAXORPLUS to provide services other than the pharmacy benefit management services and mail order pharmacy services specified above, including special research projects, reports, additional identification cards or other tasks to be specifically performed for or on behalf of CLI ENT, or (ii) to initially implement the Plan or to implement changes to the Plan MAXORPLUS is required to make system changes, then, in either event, CLIENT shall pay to MAXORPLUS an additional charge as set forth in Exhibit "A," or if not specifically set forth in Exhibit "A," as mutually agreed upon by the parties in writing before such services ("Additional Services") are provided. 5. Member Reimbursement. If an Eligible Member submits a request for reimbursement for a Covered Prescription to MaxorPlus within 90 days of service date, MaxorPlus will reimburse such Eligible Member at the contracted participating pharmacy rate. C. Joint Obligations. 1. Implementation. CLIENT and MAXORPLUS shall cooperate to achieve implementation of this Agreement in accordance with a timetable agreed to by CLIENT and MAXORPLUS. The plan for implementation of this Agreement shall be approved by CLIENT not later than sixty (60) days prior to the date when MAXORPLUS first provides services to Participating Pharmacies under this Agreement. 2. Communications. MAXORPLUS shall provide to CLIENT the following materials in implementation kits for distribution to Eligible Members: (i) introductory cover letter and (ii) mail order service information packet. Individual envelopes shall be addressed MaxorPlus Initials; Oev CLIENT Initials: by MAXORPLUS with Eligible Members names and addresses, provided CLIENT has provided MAXORPLUS such information in MAXORPLUS' standard format. Postage shall be at CLIENT'S expense in the case of distribution of implementation kits directly to Eligible Members. MAXORPLUS shall bulk ship implementation kits directly to the CLIENT at no charge. Distributions or reprints after the initial mailing of implementation kits or customized materials shall be at CLIENT'S expense. Custom materials require three (3) weeks to produce following CLIENT" approval. 3. Eligibility Data. CLIENT shall furnish MAXORPLUS Eligible Member eligibility data in an agreed -upon medium and in the format requested by MAXORPLUS. Such eligibility data updates shall identify only changes, additions or terminations of Eligible Members. CLIENT agrees that MAXORPLUS may act in reliance upon the accuracy of all data received from CLIENT under this paragraph C.3. CLIENT shall be responsible for notifying MAXORPLUS of the termination of an Eligible Member from coverage under the Plan. CLIENT shall be responsible for all claims incurred by MAXORPLUS with respect to an Eligible Member until CLIENT has provided MAXORPLUS with an updated list of Eligible Members. CLIENT shall provide the initial list of Eligible Members at least forty-five (45) days prior to implementation of services for CLIENT and a final list at least seven (7) days prior to initiation of services for CLIENT. If CLIENT submits eligibility data in a format other than that requested by MAXORPLUS, CLIENT shall incur a fee at MAXORPLUS'then prevailing rate to transform that data into MAXORPLUS' standard format. Thereafter, CLIENT shall furnish MAXORPLUS with eligibility, adds, changes and deletes updates on a weekly basis, with full eligibility loads as requested by MAXORPLUS. 4. Plan Changes. CLIENT shall notify MAXORPLUS in writing at least sixty (60) days in advance of any changes in the Plan that results in a change of any of the Pharmacy Benefit Services to be provided by MAXORPLUS under the terms of this Agreement. If such changes have a material impact on MAXORPLUS' obligations under this Agreement, MAXORPLUS may terminate this Agreement in accordance with paragraph F (2) (b) hereof or modify its charges to reflect such change in accordance with Exhibit "A". 5. Confidentiality. (a) MAXORPLUS and CLIENT shall ensure compliance with federal regulations under the Health Insurance Portability and Accounting Act (HIPAA) regarding privacy of all protected health information (PHI) and shall take steps and do all things reasonably necessary to ensure that the terms of this Agreement, all information relating to Eligible Members, and all Proprietary or Confidential Information obtained during the term of this Agreement disclosed or made use of outside the business of such other party for the purposes of meeting their obligations under this Agreement remains confidential; provided, however, that the foregoing shall not apply to information: (i) provided to voluntary accreditation agencies, government agencies or third party payors as required by Law or consented to by the affected party; (ii) reasonably required by health care providers providing health care services to Eligible Members; (iii) that either party can show was known to it prior to disclosure by the other party; or (iv) that is or becomes public knowledge through no fault of the party to whom the disclosure is made. MaxorPlus Initials: CLIENT Initials: (b) CLIENT acknowledges that the MAXORPLUS Formulary contains proprietary information of MAXORPLUS and agrees that MAXORPLUS owns all rights to the Formulary, including but not limited to, rights associated with publication, trade secrets, copyrights, trademarks, and patents, and any rights that CLIENT may have in the Formulary are hereby assigned to MAXORPLUS. Accordingly, copies in any medium distributed to CLIENT and its participating physicians remain the property of MAXORPLUS and may be used only by CLIENT and such participating physicians for the purposes and transactions contemplated by this Agreement, Other than as expressly authorized in this Agreement, no copies of the Formulary shall be distributed or disclosed except as reasonably necessary for performance of this Agreement, and in particular, no copy shall be distributed or disclosed to any competitor of MAXORPLUS. (c) CLIENT acknowledges that any unauthorized disclosure or use of MAXORPLUS information will cause MAXORPLUS immediate and irreparable injury or loss. Accordingly, should CLIENT fail to comply with this Section, MAXORPLUS shall be entitled to specific performance including immediate issuance of a temporary restraining order and/or preliminary injunction enforcing this Agreement, and to judgment for damages (including attorney's fees) caused by the breach, and to any other remedies provided by applicable law. 6. Indemnification. (a) MAXORPLUS shall defend, indemnify and hold harmless CLIENT and each of its officers, directors, employees, agents and stockholders, from and against any and all claims, liabilities, damages or expenses of any kind (including reasonable attorneys' fees and disbursements) (collectively, "Indemnified Amounts") incurred by any of those parties as a result of MAXORPLUS' negligence or breach of its obligations under this Agreement. (b) if a party seeks indemnification under this Agreement, that party shall notify the other in writing within a reasonable time 30 days of the assertion of any claim, or the commencement of any action or proceeding, for which indemnity may be sought under this Agreement. Failure to notify the other party shall result in the waiver of indemnity rights with respect to such claim, suit, action or proceeding. The parties shall cooperate with each other in the defense and settlement of any such claim, action or proceeding. D. Obligations of Client. 1. Payment. CLIENT shall pay MAXORPLUS for the Pharmacy Benefit Services provided by MAXORPLUS under the terms of this Agreement in accordance with the schedules set forth in Exhibit "A". CLIENT shall also pay to MAXORPLUS all amounts to be disbursed on its behalf to Participating Pharmacies by MAXORPLUS. In no event shall MAXORPLUS have any obligation to forward any claims payments to participating pharmacies unless and until CLIENT has submitted payment to MAXORPLUS when required. CLIENT shall remain responsible for payment of all claims. 2. Securit . MAXORPLUS agrees that based upon CLIENT'S present financial condition, MAXORPLUS shall not require security; provided, however, if at anytime and from time to time during the term of this Agreement MAXORPLUS shall determine, based on MaxorPlus Initials: CLIENT Initials: Claims volume, payment record and/or CLIENT'S latest financial information, that there are reasonable grounds for insecurity on the part of MAXORPLUS as to the ability of CLIENT to meet its financial commitments hereunder as they become due, MAXORPLUS shall have the right to require CLIENT to provide a fetter of credit from the CLIENT'S bank or security deposit in such amount and form and at such time as MAXORPLUS deems necessary, not to exceed two cycles of claims activity. CLIENT shall provide such security within ten (10) days of MAXORPLUS' request. CLIENT agrees to furnish audited financial statements to MAXORPLUS from time to time upon MAXORPLUS' request. Such financial statements shall be kept confidential by MAXORPLUS and used solely for internal review purposes to determine credit requirements. 3. Pricing Changes. After the initial term of this Agreement, MAXORPLUS and CLIENT may renegotiate the Administrative Fees or Finance Charges applicable to a Plan by MAXORPLUS giving CLIENT ninety (90) days' prior written notice of expiration and request to renegotiate. 4. Control of Plan. CLIENT shall have sole authority to control and administer the Plan. Nothing in this Agreement shall be deemed to confer upon MAXORPLUS the (a) status of fiduciary as defined in either the Employee Retirement Income Security Act of 1974, as amended, or the Americans with Disabilities Act ("ADA") or (b) any responsibility for the terms or validity of the Plan. CLIENT represents that it has all necessary authorizations from Eligible Members to receive, review and audit Patient -Specific Data. To the extent permitted by law, CLIENT agrees to defend, indemnify, and hold harmless MAXORPLUS and each of its officers, directors, employees, agents, and stockholders from and against any and all claims, liabilities, damages, or expenses of any kind (including reasonable attorney's fees and disbursements) which MAXORPLUS may incur as a result of any claim by an employee or former employee of CLIENT or any of its affiliates under law that protects the rights of such employees and their beneficiaries, including, without limitation, the Employee Retirement Income Security Act ("ERISA") and the Americans With Disabilities Act ("ADA"). 5. Disclosure Obligations. CLIENT acknowledges and agrees that it is responsible for disclosing to Eligible Members any and all matters relating to the Plan as are required by law to be disclosed, including any matter relating to the calculation of co - payments, co-insurance amounts, deductibles or any other amounts that are payable by an Eligible Member in connection with the Plan. CLIENT further agrees to inform Eligible Members that claims submitted after 90 days from origination will not be covered by MaxorPlus. 6. Compliance with Law. CLIENT agrees to comply with ail Laws applicable to its prescription drug benefit plan. CLIENT acknowledges that MAXORPLUS shall have no responsibility to advise CLIENT regarding CLIENT's compliance with any applicable law, including, without limitation, ERISA, the ADA, and tax laws. MAXORPLUS makes no representation or warranty that the Plan design selected by CLIENT shall be in compliance with applicable law. Upon CLIENT'S request and at its expense, MAXORPLUS shall cooperate and take reasonable steps to comply with any laws applicable to the creation and maintenance of a pharmacy network, including any willing provider laws. CLIENT shall to MaxorPlus Initials: CLIENT Initials: furnish MAXORPLUS, in a timely manner, all information necessary for such cooperation and compliance efforts. 7. Confirmation Reports. From time to time, MAXORPLUS may provide CLIENT with reports confirming (i) all or some portion of the Plan information submitted to MAXORPLUS, (ii) member enrollment or eligibility data, (iii) claims or billing activity during a specific period, and/or (iv) any action or actions taken by MAXORPLUS in performing administrative services or additional services hereunder. CLIENT shall review such report and notify MAXORPLUS in writing of any errors or objections within thirty (30) days of receipt of the report. Until CLIENT notifies MAXORPLUS of any errors or objections, MAXORPLUS shall be entitled to rely on the information contained in the report. if CLIENT does not notify MAXORPLUS of any errors or objections within such thirty (30) day period, the information contained in the report shall be deemed accurate, complete and acceptable to CLIENT. 8. Other Rebate Arrangements. With respect to Eligible Members covered by this Agreement, CLIENT will not participate in any other formulary or similar discount program (including any such program which may be available through a mail order pharmacy designated by CLIENT) not managed by MAXORPLUS during the term of the Agreement and shall not independently create any formulary during the term of the Agreement. Also, with respect to such Eligible Members, CLIENT agrees not to enter into any direct or indirect contracts with pharmaceutical manufacturers for discounts during the term of the Agreement or any extension thereof. Nothing in this section shall prohibit CLIENT from entering into arrangements with other pharmaceutical management companies offering formulary services after the term of the Agreement. E. Billing and Funding; Remedies. 1. Payment Due Date and Service Fee. MAXORPLUS shall invoice CLIENT at the time specified on Exhibit B to this Agreement. All payments by CLIENT shall be made within fifteen (15) days after invoice date. Late payments shall bear a service fee of one and one-half percent (1.5%) for each thirty (30) days that payment is late, beginning on the sixteenth (16th) day after invoice date; provided however, that if the service fee charged would exceed the maximum legal rate for interest permitted by law, the service fee shall be reduced to the maximum amount of periodic interest permitted by law. 2. Certain Remedies. If at any time CLIENT shall fail to pay MAXORPLUS by the due date the amount owing to MAXORPLUS hereunder, MAXORPLUS shall have the right, upon two (2) business days written notice to CLIENT, to (i) suspend performance of any and all of MAXORPLUS' obligations under or in connection with this Agreement, (including MAXORPLUS' obligation to process claims using the POS System), (ii) immediately advise CLIENT that MAXORPLUS' POS system is not available in connection with the Plan, (iii) apply all or any portion of any security posted by CLIENT with MAXORPLUS to CLIENT'S delinquent account, and (iv) set off against any amounts otherwise payable to CLIENT under this Agreement (including, if any, rebates MAXORPLUS receives from a manufacturer on behalf of the CLIENT) any amounts due from CLIENT under this Agreement. CLIENT shall be responsible for all costs of collection and agrees to reimburse MAXORPLUS for such costs and expenses, including reasonable attorney's fees. Nothing in this Agreement shall limit, MaxorPius Initials: CLIENT Initials: and the parties agree that in addition to the rights specified in this Section MAXORPLUS shall retain, any and all rights MAXORPLUS may have at law, equity or under this Agreement. F. Term and Termination 1. Term. This Agreement shall become effective on April 1, 2006 (the "Effective Date") and thereafter shall continue to be in effect for three (3) year(s). The term shall be automatically renewed for additional one (1) year periods, unless terminated in accordance with paragraph F (2) hereof, or as otherwise provided in this Agreement. 2. Termination. (a) Either party may terminate this Agreement upon thirty (30) days prior written notice to the other party in the event of a material breach by such other party and the failure of such other party to cure such breach within the thirty (30) day period following such notice. (b) Either party may terminate this Agreement as of the end of the primary term of this Agreement, or any renewal period thereafter, by providing written notice to the other party of their intent to terminate the Agreement not more than one hundred twenty (120) days but not less than ninety (90) days from the end of the primary term or renewal period. (c) MAXORPLUS may terminate this Agreement upon thirty (30) days prior written notice to CLIENT if CLIENT changes, modifies or amends the Plan in a manner that, in the sole discretion of MAXORPLUS, materially or adversely affects MAXORPLUS or significantly increases the responsibilities of MAXORPLUS under this Agreement. (d) Either party may terminate this Agreement at anytime upon written notice to the other party in the event of any of the following: (i) the commencement of any proceedings, whether under court supervision or otherwise, for the liquidation of the other party; (ii) the insolvency of the other; (iii) the appointment of a receiver or similar officer for the other; or (iv) the filing of a petition in bankruptcy by or against the other under any state or federal bankruptcy statute or debtors law for its relief or reorganization or forthe composition, extension, arrangement, or readjustment of its obligations. 3. Obligations Upon Termination. Termination of this Agreement shall have no effect upon the rights and obligations of the parties arising out of any transactions occurring prior to the effective date of such termination. In the event of termination of this Agreement for any reason, MAXORPLUS shall continue to process mail order prescriptions not requiring clarification that are received prior to the termination date. CLIENT shall remain liable to MAXORPLUS for all fees incurred prior to such termination and for all expenses incurred by MAXORPLUS in forwarding to CLIENT Prescriptions received thereafter. Duties of confidentiality under the Agreement shall survive its termination and shall continue for six (6) years following termination (unless such materials have been previously returned or destroyed), at which time all remaining confidential information retained by one party of the other shall be returned or destroyed. 12 MaxorPlus Initials: CLIENT Initials: _ G. Miscellaneous 1. Assignment. Neither party may assign this Agreement without the prior written consent of the other party, provided, however, that MAXORPLUS may assign this Agreement to any of its affiliates at anytime or as part of a sale of all or substantially all of its assets. This Agreement is a service contract specific to the CLIENT, and MAXORPLUS cannot be required without its consent by assignment to perform its services for any entity other than the CLIENT. 2. Compliance with Law. Each party shall comply with the provisions of all applicable Laws and regulations in connection with the subject matter of this Agreement. Neither party shall make payments or perform any services under this Agreement that would be prohibited by Law. No part of this Agreement shall be construed to induce or encourage the referral of patients, and no payment made pursuant to this Agreement or any other agreement between MAXORPLUS and CLIENT shall be construed as an inducement for the purchase, lease, order or arrangement for the furnishing of health care products or services. 3. Exclusivity. CLIENT shall make MAXORPLUS the exclusive provider to its Eligible Members of the Pharmacy Benefit Management Services during the term of this Agreement. 4. Force Maieure. Except for payment obligations, neither party shall be liable for failure or delay of performance arising from an act of God or other events beyond control of such party; including the acts of a regulatory agency, fires, floods, explosions, strikes, labor stoppages, war and rebellion. 5. Limitation of Liability. Except as otherwise expressly set forth in this Agreement, MAXORPLUS makes no representations or warranties, express or implied, including but not limited to any warranty of merchantability or fitness for a particular purpose. In no event shall MAXORPLUS be liable for any incidental or consequential damages. 6. Amendment of Agreement. This Agreement may not be modified except in writing signed by both parties. 7. Governing Law/Change in Law. This Agreement and its interpretation shall be governed by the laws of the State of Texas with venue in PotterLubbock County, Texas. If there occurs any change in law which materially alters the rights or obligations of either party under this Agreement, the parties shall equitably adjust the terms of this Agreement to take into account such change in law. If the parties are unable to agree upon an equitable adjustment within sixty (60) days after either party notifies the other of such a change in law, this Agreement shall terminate. 8. Severability. If any provision of this Agreement is held to be invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect the remainder of this Agreement, which shall be in full force and effect and enforceable in accordance with its remaining terms. ]3 MaxorPlus Initials: AZ CLIENT initials: 9. Entire Agreement: Waiver. This Agreement supersedes all prior or contemporaneous understandings or contracts, and constitutes the entire agreement existing between the parties regarding the subject matter of this Agreement. No waiver or discharge of any breach of this Agreement shall be effective unless it is in writing signed by both parties. Any waiver of any breach of any provision of this Agreement shall not be a waiver of any subsequent breach of any provision of this Agreement. 10. Notices. Any notice given under this Agreement shall be in writing and shall be deemed received if sent by hand delivery, facsimile transmission, receipt confirmed, overnight courier that provides confirmation of delivery, or certified mail, return receipt requested, to the applicable party at its address set forth beneath its signature to this Agreement, or to such other address or to the attention of such other person as either party may designate in writing pursuant to this Section. 11. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 12. Agreement Dispute Resolution. Should a dispute arise concerning either party's failure to fulfill its obligations under this Agreement, the aggrieved party will seek resolution of the dispute by good -faith negotiations between the CEO of each party or his or her designee. Should the negotiations fail to resolve the dispute within fifteen (15) days of their beginning, the parties shall attempt, in good faith, to settle the dispute through mediation. Failure to agree on a mediator will be resolved by submitting the dispute to the local equivalent of a dispute resolution center. If the mediation fails to resolve the dispute, the parties agree to submit the matter to binding arbitration in the venue of the responding party under the rules of the American Arbitration Association. 13. Exhibits. The following exhibits are made a part of this Agreement. EXHIBIT A - Client Payments EXHIBIT B - Invoice Schedule EXHIBIT C - Plan Description and Co -payments EXHIBIT D - MaxorPlus Mail Service Pharmacy Clinical Pharmacy Services EXHIBIT E — MaxorPlus Code of Ethics EXECUTED this day of 2006 by affixing an authorized signature hereto and initialing each page in the spaces provided. 14 MaxorPlus Initials: CLIENT Initials: MAXORPLUS, LTD. CITY OF LUBBOCK By: (iPABy: hn Q. Ward Title: CEO Date: A8 0r 320 South Palk, Suite 200 Amarillo, Texas 79101 Fax No: (806) 324-5495 ATTEST: Garza, City S APPROVED AS TO CZVE O TENT: V-VA Scott Snider Director of Human Resources APPROVED AS TO FORM: �C n M. Knight Assistant City Attorney MaxorPlus Initials: _ 15 CLIENT initials: Title: Date: March 8, 2006 Fax No: 806-775-3983 rc W0ougal, Mayor EXHIBIT "A" CLIENT PAYMENTS 1. Retail Prescriptions. For each Prescription dispensed by a Participating Pharmacy to an Eligible Member, CLIENT shall reimburse MAXORPLUS an amount equal to the MAXORPLUS Pharmacy Reimbursement Rate. Pharmacy Reimbursement Rate — For the purpose of this Exhibit A "Pharmacy Reimbursement Rate" means for (i) brand name drugs, AWP minus 13 to 15 percent plus $2.50 fill fee, and (ii) generic drugs, MAC plus $2.50 fill fee. CLIENT is responsible for the payment of any applicable sales or use taxes, and CLIENT shall reimburse MAXORPLUS for all taxes paid on its behalf to Participating Pharmacies. If CLIENT requests MAXORPLUS to add a pharmacy to the network that is contracted at different reimbursement rates than set out above, CLIENT shall be invoiced at the applicable contracted MAXORPLUS Pharmacy Reimbursement Rate. 2. Mail Order Pharmacy. For each Prescription dispensed by the MAXORPLUS Mail Order Pharmacy to an Eligible Member, CLIENT shall pay MAXORPLUS net acquisition cost plus $12.50 fill fee less co -payment and deductibles established by CLIENT. In the event an Eligible Member submits to MAXORPLUS a Co -payment in an insufficient amount, and MAXORPLUS is unable to collect the correct Co -payment amount from the Eligible Member, then MAXORPLUS may invoice CLIENT for the amount of the uncollected Co-payment(s), and CLIENT shall be liable for payment of such co -payment amount. 3. Chronic IniectablelSpecialty Pharmacy. For each prescription dispensed by Maxor Specialty to an eligible member, CLIENT shall pay MAXORPLUS AWP less 17% plus $2.50 less co -payment as established by CLIENT for Tier 1 Specialty Drugs; AWP less 19% plus $2.50 less co -payment as established by CLIENT for Tier 2 Specialty Drugs; AWP less 21 % plus $2.50 less co -payment as established by CLIENT for Tier 3 Specialty Drugs; or AWP less 24% plus $2.50 less co -payment as established by CLIENT forTier4 Specialty Drugs as designated by MAXORPLUS. The AWP less the applicable discount plus $2.50 shall cover shipping fees and necessary overnight delivery due to stability of medications. In the event an Eligible Member submits to MAXORPLUS a Co -payment in an insufficient amount, and MAXORPLUS is unable to collect the correct Co -payment amount from the Eligible Member, then MAXORPLUS may invoice CLIENT for the amount of the uncollected Co-payment(s) on a regular basis, and CLIENT shall be liable for payment of such co -payment amount. 4. Special Reimbursement for Certain Drugs. Certain drugs that become available on the market from time to time will be priced separately from, and thus not subject to the reduced contracted reimbursement rate, due to, among other things, specialized manufacturer processes, limited availability or extraordinary shipping requirements. Such drugs include compounds. MAXORPLUS shall provide CLIENT with a list of such drugs, and their corresponding reimbursement rates (which are generally no less than full AWP), upon request. Participating Pharmacies may dispense these drugs to Eligible Members unless the 16 MaxorPlus Initials: CLIENT Initials: CLIENT'S plan design would otherwise exclude these drugs or the CLIENT notifies MAXORPLUS in writing of its objections. CLIENT hereby agrees to the following: All payments made by CLIENT to MAXORPLUS shall include all applicable fees, including, but not limited to ingredient cost and dispensing fee. 5. MaxorPlus Mail Order Pharmacy Clinical Pharmacy Services. a. Prescription Clinical Intervention. CLIENT shall receive 100% of all savings realized as a result of MAXORPLUS providing the Prescription Clinical Intervention Services described in Exhibit D. 6. Administrative Services and Fees. Administrative Fee* Rebate Sharing ID Cards (additional or replacement) Administrative Prior Authorizations (PA) Clinical Prior Authorizations (PA) Paper Claims Processing Manual Eligibility Data Entry Formulary Postage, Printing and Distribution $3.00 per prescription 100% to CLIENT No Charge No Charge No Charge No Charge No Charge No Charge * Administrative fee is subject to an annual inflation adjustment according to the Consumer Price Index. 7. Additional Services - With the exception of the costs incurred as part of the services described in paragraph B of this Agreement, CLIENT shall be responsible for all mutually agreed upon costs and charges incurred by MAXORPLUS in connection with this Agreement. Such costs shall include costs associated with responding to CLIENT requests, costs necessitated by the acts or omissions of CLIENT and any cost incurred by MAXORPLUS in performing services in conjunction with this Agreement which may be requested or required of MAXORPLUS and not specifically included in the scope of services described in paragraph B. MAXORPLUS and CLIENT agree to negotiate in good faith the cost of any services requested by CLIENT outside the scope of services described in Paragraph B of this Agreement. to MaxorPlus Initials: b�V CLIENT Initials: EXHIBIT "B" INVOICE SCHEDULE Invoices shall be issued according to the following schedule: Retail and Mail Order Prescription Claims Payment Administrative Service Fees Additional Service Fees and Costs MAXORPLUS Mail Order Pharmacy Prescription Clinical Intervention Services 18 MaxorPlus Initials: CLIENT Initials: Semi-monthly Semi-monthly Semi-monthly Monthly EXHIBIT "C" PRESCRIPTION DRUG RIDER (Drug Rider to Follow) 19 MaxorPlus Initials: CLIENT Initials: City of Lubbock Summary of Prescription Benefit Coverage Iniectables Covered At Retail/Mail Order Network Pharmacies Anaphylactic Kits (ex. Epi-pen, Anakit) Byetta Calcitonin (Miacalcin) CyanocobaJamin (Vitamin B-12) Desmopressin (DDAVP) Dihydroergotamine (DAE.-45) Glucagon Imitrex Insulin Symlin Vitamin K Xolair- limited distribution Iniectables Covered Through Maxor Specialty Pharmacy Actimmune Alferon-N Apokyn Aranesp Arixtra Avonex Betaseron Copaxone Eligard Enbrel Epogen Forteo Fuzeon Fragmin Geref Growth HormoneslGrowth Hormone Releasing Hormones Histrelin Humatrope Humira Infergen Innohep Interferons Intron-A Kineret Leukine Leuproiide Lovenox Lupron/Lupron Depot Myeloid Stimulants Neumega Neupogen Norditropin Normiflo Nutropin/Nutropin AQ Octreotide Orgaran Procrit Protropin Raptiva Rebetron Rebif Roferon-A Saizen Sandostatin Serostim Somavert Supprelin 7-06-LF City of Lubbock Summary of Prescription Benefit Coverage Nan-Iniectables Covered Through Maxor Specialty Pharmacy Oniy Arava Copegus Iressa Nebupent Pulmozyme Rebetol Ribasphere Ribavirin Sensipar Stimate Nasal Spray Ta rceva Temodar Tobi Valcyte Virazole Xeloda Client Signatur City of Lubbock Date 6,Ok 7-Us-LF EXHIBIT "D" MAXORPLUS MAIL SERVICE PHARMACY CLINICAL PHARMACY SERVICES Prescription Clinical Intervention Services MAXORPLUS shall: A. Analyze available patient data to determine the appropriateness and cost effectiveness of current Mail Order Prescriptions provided to Eligible Members; B. Based upon the foregoing analysis, MAXORPLUS shall contact the prescriber where appropriate to suggest modifications to the prescribed therapy to either a therapeutic or generic equivalent; and C. Dispense Prescriptions as authorized by the prescriber. 20 MaxorPlus Initials: CLIENT Initials: Resolution No. 2007—RO523 EXHIBIT "E" MAXORPLUS CODE OF ETHICS Maxor National Pharmacy Services Corporation is committed to always representing the best interests of its Clients in all PBM activities under its COMPLETE DISCLOSURE PRICING program. To clarify Maxor's pledge to its Clients under this program, the following code of ethical behavior has been adopted by Maxor and is incorporated into every COMPLETE DISCLOSURE PRICING contract with Maxor: • Maxor pledges its total dedication to the highest ideals of honesty and integrity in all PBM activities. • Maxor shall strive to provide the highest level of service possible and will always prioritize the best interests of the Client and its employees in all PBM activities. • Maxor pledges to fully disclose all financial activities related to every transaction affecting the Client. • Maxor pledges that it will always use its best efforts to obtain the best value on all drug purchases for the Client in both the retail network and through Maxor's mail-order pharmacy. • Maxor pledges to always bill the Client the same discounted AW P or MAC price that it pays the network pharmacy. • Maxor pledges that it will never use "spread pricing" for purchasing drugs sold in its mail order pharmacy. • Maxor pledges that it will never use repackaged or relabeled NDC numbers for its mail order pricing unless the unit cost to the Client is less than the oiginal manufacturer's price. • Maxor pledges to pass through to the Client all discounts from prime vendors. • Maxor pledges to pass 100% of all rebates, administrative fees and other revenue received from drug manufacturers through to the Client. • Maxor guarantees that it will never sell data related to Client's members or Client's account without first obtaining Client's approval, and when data is sold, 100% of the revenue from such a transaction will be passed through to the Client. • Maxor guarantees that the only revenue retained by Maxor under its COMPLETE DISCLOSURE PRICING program shall be the administrative fees charged to the Client and the dispensing fees charged on prescriptions filled in Maxor's mail-order pharmacy. All other revenues and expenses shall flow through to the Client. • Maxor pledges to always disclose all fees or commissions associated with the Client's account that are paid to Third Party Administrators, Brokers or Consultants. • Maxor pledges to use its best efforts to provide data related to Client's activities in a timely fashion upon request. • Maxor pledges its total commitment to providing a fully auditable program, including allowing Client's auditors access to all rebate contracts and purchase agreements with drug manufacturers or suppliers, as well as access to Client's billing file and pharmacy payment file for all PBM activity. 21 MaxorPlus Initials; Al2 CLIENT Initials: